SCHEMBL6401063

SCHEMBL6401063

O=P(O)(O)Sc1ccc(O)cc1C(O)(O)Cc1cccc(O)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGPS1 O95749 2/20 0.35
ENPP2 Q13822 1/20 0.35
DRD2 P14416 2/20 0.33
DRD1 P21728 2/20 0.33
TAAR1 Q96RJ0 1/20 0.33
FDPS P14324 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
PKM P14618 1/20 0.33
ALOX15 P16050 1/20 0.33
NFKB1 P19838 1/20 0.33
MAPK1 P28482 1/20 0.33
IDO1 P14902 1/20 0.32
MIF P14174 1/20 0.32
DRD4 P21917 1/20 0.32
DRD5 P21918 1/20 0.32
DRD3 P35462 1/20 0.32
KMT2A Q03164 1/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6396485 0.90 GGPS1 (0.35) GGPS1ENPP2DRD2DRD1TAAR1
SCHEMBL6402566 0.88 ESR1 (0.35) FDPSBLM
SCHEMBL6398622 0.87 DRD2 (0.38) ENPP2DRD2DRD1TAAR1IDO1
SCHEMBL6402090 0.85 MGLL (0.38) DRD2DRD1TAAR1FDPSIDO1
SCHEMBL6394418 0.81 GGPS1 (0.35) GGPS1ENPP2DRD2DRD1TAAR1
SCHEMBL6401068 0.80 GGPS1 (0.40) GGPS1ENPP2DRD2DRD1TAAR1
SCHEMBL6396948 0.80 GGPS1 (0.34) GGPS1ENPP2DRD2DRD1TAAR1
SCHEMBL6402166 0.77 ESR1 (0.34) TAAR1FDPSCYP1A2CYP3A4ALOX15
SCHEMBL6404559 0.77 IDO1 (0.39) ENPP2DRD2DRD1TAAR1FDPS
SCHEMBL6396486 0.77 GGPS1 (0.40) GGPS1ENPP2DRD2DRD1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 GGPS1 1752/4885ENPP2 259/4885DRD2 1797/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 GGPS1 2058/4885ENPP2 270/4885DRD2 1795/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 GGPS1 1752/4885ENPP2 259/4885DRD2 1797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.